Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 8/20 | 0.38 |
| ▸ | CTSL | P07711 | 7/20 | 0.38 |
| ▸ | CTSK | P43235 | 7/20 | 0.38 |
| ▸ | CTSS | P25774 | 6/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11985580 | 1.00 | CTSB (0.38) | CTSBCTSLCTSKCTSSSMN1; SMN2 | |
| SCHEMBL8236530 | 0.86 | SMN1; SMN2 (0.39) | CTSBCTSLCTSKCTSSSMN1; SMN2 | |
| SCHEMBL11936283 | 0.86 | SMN1; SMN2 (0.39) | CTSBCTSLCTSKCTSSSMN1; SMN2 | |
| SCHEMBL841615 | 0.83 | L3MBTL1 (0.37) | CTSBCTSLCTSKCTSSSMN1; SMN2 | |
| SCHEMBL841614 | 0.83 | L3MBTL1 (0.37) | CTSBCTSLCTSKCTSSSMN1; SMN2 | |
| SCHEMBL842048 | 0.83 | SMN1; SMN2 (0.40) | CTSBCTSLCTSKCTSSSMN1; SMN2 | |
| SCHEMBL842049 | 0.83 | SMN1; SMN2 (0.40) | CTSBCTSLCTSKCTSSSMN1; SMN2 | |
| SCHEMBL16328219 | 0.82 | SMN1; SMN2 (0.38) | CTSBCTSLCTSKCTSSSMN1; SMN2 | |
| SCHEMBL13338252 | 0.82 | SMN1; SMN2 (0.38) | CTSBCTSLCTSKCTSSSMN1; SMN2 | |
| SCHEMBL14416450 | 0.82 | CTSB (0.38) | CTSBCTSLCTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247532-B2 | Deuterated hepatitis C protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-21 | — | — | US | disclosed |
| US-20110071074-A1 | DEUTERATED HEPATITIS C PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-24 | — | — | US | disclosed |
| US-20070225297-A1 | Deuterated hepatitis C protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225297-A1 | Deuterated hepatitis C protease inhibitors | PEPD, CTRL, CTSC | CTSB 63/4885CTSL 24/4885CTSK 66/4885 |
| US-20110071074-A1 | DEUTERATED HEPATITIS C PROTEASE INHIBITORS | PEPD, CTRL, CTSC | CTSB 63/4885CTSL 24/4885CTSK 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.